Segall Bryant & Hamill’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Segall Bryant & Hamill’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.8M	Sell	426,412 -21,684	-5%	-$718K	0.18%	192
2025 Q4	$14.7M	Sell	448,096 -39,100	-8%	-$1.26M	0.2%	180
2025 Q3	$16.9M	Sell	487,196 -13,881	-3%	-$444K	0.22%	158
2025 Q2	$14M	Sell	501,077 -150,384	-23%	-$4.03M	0.2%	172
2025 Q1	$16.4M	Sell	651,461 -34,406	-5%	-$869K	0.25%	126
2024 Q4	$18.9M	Sell	685,867 -19,781	-3%	-$551K	0.26%	120
2024 Q3	$20.3M	Sell	705,648 -93,431	-12%	-$2.54M	0.28%	112
2024 Q2	$19.8M	Sell	799,079 -68,963	-8%	-$1.96M	0.35%	91
2024 Q1	$28M	Sell	868,042 -6,686	-0.8%	-$249K	0.52%	55
2023 Q4	$35.6M	Buy	874,728 +136,737	+19%	+$5.03M	0.69%	36
2023 Q3	$25.5M	Buy	737,991 +346,630	+89%	+$13.5M	0.3%	105
2023 Q2	$15.9M	Buy	391,361 +91,970	+31%	+$3.75M	0.17%	160
2023 Q1	$11.6M	Buy	+299,391	New	+$12.3M	0.12%	207

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Segall Bryant & Hamill's LKFT Position: Q1 2026 in Review

Segall Bryant & Hamill reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 4.8% in Q1 2026, selling an estimated $718K and leaving 426,412 shares worth $12.8M. The position accounts for 0.18% of the portfolio, ranked #192.

Segall Bryant & Hamill first reported a position in LKFT in Q1 2023 and has held it in 13 quarters since. The position peaked at $35.6M in Q4 2023. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

Segall Bryant & Hamill held 426,412 shares of Lakefront Biotherapeutics American Depositary Shares worth $12.8M as of Q1 2026.
Segall Bryant & Hamill sold 21,684 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $718K.
Lakefront Biotherapeutics American Depositary Shares made up 0.18% of Segall Bryant & Hamill's portfolio in Q1 2026, its #192 holding.
Segall Bryant & Hamill first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2023 and has held it in 13 quarters since.
Segall Bryant & Hamill's Lakefront Biotherapeutics American Depositary Shares position peaked at $35.6M in Q4 2023.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.